ertapenem has been researched along with Diabetic Feet in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (53.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Citron, DM; Fernandez, HT; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, YA | 1 |
| Fang, W; Liu, W; Song, L; Sun, W; Wang, C | 1 |
| Knezevic, NN; Tinevez, D | 1 |
| Carvalho, VC; Lima, AL; Oliveira, PR; Peixoto de Miranda, EJ | 1 |
| Castaing, N; Cooper, A; Dartois, N; Dukart, G; Embil, JM; Lauf, L; Maroko, R; Mitha, I; Ozsvár, Z; Regöly-Mérei, J; Sabol, MB; Yan, J | 1 |
| Munckhof, WJ; Oo, Y; Packham, D; Yau, W | 1 |
| Gan, WJ; Mu, SM; Ran, XW; Shen, JF; Wang, J; Xian, Y; Xu, ZR; Yan, XD; Yuan, GY; Zhang, BS | 1 |
| Carmeli, Y; Jansen, JP; Kumar, R | 1 |
| Edmonds, M | 1 |
| Burian, A; Burian, B; Höferl, M; Jäger, W; Riedl, M; Sauermann, R; Stella, A; Theurer, S; Zeitlinger, M | 1 |
| Abramson, MA; Armstrong, DG; Citron, DM; Lipsky, BA; Morgenstern, DE; Tice, AD | 1 |
| Armstrong, DG; Bevilacqua, NJ; Rogers, LC | 1 |
| Abramson, MA; Armstrong, DG; Lipsky, BA; Polis, AB; Sheehan, P; Tice, AD | 1 |
| Abramson, MA; Hoey, CT; Lipsky, BA; Tice, AD; Turpin, RS; Wu, J | 1 |
| Bouziges, N; Jourdan, N; Lavigne, JP; Lemaire, X; Richard, JL; Sotto, A | 1 |
4 review(s) available for ertapenem and Diabetic Feet
| Article | Year |
|---|---|
[Microbiology of diabetic foot infections: role of ertapenem].
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Drug Resistance, Bacterial; Ertapenem; Humans; Microbial Sensitivity Tests | 2013 |
Ertapenem-associated psychosis and encephalopathy.
Topics: Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Ertapenem; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Psychoses, Substance-Induced; Severity of Illness Index; Wound Infection | 2014 |
The treatment of diabetic foot infections: focus on ertapenem.
Topics: Administration, Oral; Anti-Bacterial Agents; beta-Lactams; Combined Modality Therapy; Debridement; Diabetic Foot; Drug Administration Schedule; Ertapenem; Humans; Infusions, Intravenous; Osteomyelitis; Severity of Illness Index; Treatment Outcome; Vascular Surgical Procedures | 2009 |
Ertapenem for diabetic foot infections.
Topics: Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Ertapenem; Humans | 2006 |
3 trial(s) available for ertapenem and Diabetic Feet
| Article | Year |
|---|---|
Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Humans; Male; Middle Aged; Minocycline; Nausea; Osteomyelitis; Tigecycline; Treatment Outcome; Vancomycin; Vomiting; Young Adult | 2014 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactams; China; Diabetic Foot; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; Young Adult | 2016 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Double-Blind Method; Drug Administration Schedule; Ertapenem; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Severity of Illness Index; Treatment Outcome | 2005 |
8 other study(ies) available for ertapenem and Diabetic Feet
| Article | Year |
|---|---|
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Diabetic Foot; Doripenem; Humans; Microbial Sensitivity Tests | 2008 |
Distribution of microbes and antimicrobial susceptibility in patients with diabetic foot infections in South China.
Topics: Amikacin; Anti-Bacterial Agents; Coinfection; Diabetes Mellitus; Diabetic Foot; Ertapenem; Gram-Negative Bacteria; Humans; Meropenem; Retrospective Studies; Tigecycline | 2023 |
Topics: Aged, 80 and over; Anti-Bacterial Agents; Arthritis, Gouty; Citrobacter koseri; Debridement; Diabetic Foot; Enterobacteriaceae Infections; Ertapenem; Humans; Male; Osteomyelitis; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; Vancomycin | 2019 |
Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cost-Benefit Analysis; Decision Trees; Diabetic Foot; Direct Service Costs; Drug Costs; Drug Resistance, Bacterial; Ertapenem; Humans; Models, Biological; Models, Econometric; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Treatment Outcome; United Kingdom | 2009 |
Tissue pharmacokinetics of ertapenem at steady-state in diabetic patients with leg infections.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Ertapenem; Female; Humans; Male; Middle Aged; Plasma; Skin; Young Adult | 2013 |
Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Ertapenem; Female; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Treatment Failure | 2007 |
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Drug Administration Schedule; Drug Combinations; Ertapenem; Female; Health Care Costs; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
[In vitro activity of ertapenem against strains isolated from diabetic foot infections].
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Diabetic Foot; Drug Evaluation, Preclinical; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Inpatients; Microbial Sensitivity Tests; Species Specificity; Staphylococcal Infections | 2008 |